Skip to content
PubMed This is a summary of 18 peer-reviewed journal articles Updated
Occupational medicine

Standard of Care and Treatment Realities

At a Glance

Silicosis cannot be cured or have its lung scarring reversed. The most important steps are complete avoidance of silica dust, regular monitoring, treatment of breathing problems and complications, and transplant evaluation for selected patients with advanced disease.

Silicosis is a permanent condition. Because the silica particles trapped in your lungs cannot be broken down or removed by the body, there is currently no medical cure that reverses the lung scarring [1][2]. Management focuses on preventing further damage, treating treatable complications, managing symptoms, and, in advanced cases, assessing eligibility for lung transplantation [3][4].

The Critical First Step: Avoiding Exposure

The most important action you can take after a diagnosis is to avoid all further exposure to silica dust as completely as possible. This stops new particles from entering your lungs [4][5].

However, stopping exposure does not guarantee the disease will stop progressing. In one study following workers who left the engineered stone industry, over half still saw their lung scarring worsen over a four-year period [6]. Because the particles already inside your lungs continue to trigger inflammation, long-term monitoring remains essential even if you change careers [7][8].

Practical Action: Work with an occupational medicine or workplace-safety specialist. If immediately leaving your job is financially impossible, they can help implement strict engineering and dust controls. Note that personal respirators are a last line of defense and are not a substitute for proper workplace dust extraction and ventilation.

Supportive Care and Managing Complications

While the scar tissue itself cannot be reversed, many of the issues that make it hard to breathe can be treated:

  • Inhalers for Airway Obstruction: If you have coexisting COPD, asthma, or obstructed airways from the dust, bronchodilator inhalers can help open your airways and relieve shortness of breath.
  • Pulmonary Rehabilitation: This supervised program includes exercise training, breathing techniques, and nutritional advice. It helps you maximize the lung function you have and improves your quality of life [1][4].
  • Supplemental Oxygen: If a formal medical assessment shows that your blood oxygen drops significantly while resting, exercising, or sleeping, your doctor may prescribe oxygen therapy. While oxygen does not reverse fibrosis, it reduces the strain on your heart [1]. Oxygen is a medical treatment that should not be started or adjusted without clinical advice, and it requires strict fire and smoking safety precautions.
  • Treating Complications: Conditions like pulmonary hypertension (high blood pressure in the lungs), bacterial infections, or sleep apnea require separate evaluation and targeted treatments.

Lung Transplantation

For selected patients with end-stage silicosis—particularly those with severe Progressive Massive Fibrosis (PMF) or rapid lung decline—a lung transplant may be an option to consider [9][10].

  • Selection: A transplant is a major surgery and is not a guaranteed cure. Doctors consider a transplant only after a multidisciplinary assessment of your symptoms, FEV1 and DLCO numbers, overall health, oxygen needs, and comorbidities [11].
  • Outcomes: Survival rates and outcomes depend heavily on center expertise, age, the presence of pulmonary hypertension, and active infection status. Both single and double lung transplants are performed; the best choice for you is determined by the transplant center based on your specific medical details [12][13].

Unproven and Experimental Treatments

You may read about other treatments, but it is important to know where the science stands today:

  • Whole-Lung Lavage (WLL): This procedure involves washing the lungs with a saline solution. While it is sometimes used for a very rare complication called acute silicoproteinosis, there is no evidence that WLL prolongs survival in patients with standard chronic or accelerated silicosis, and it is not considered a standard treatment [14][15].
  • Antifibrotic Medications: Drugs like nintedanib and pirfenidone are approved to treat other types of lung scarring (like idiopathic pulmonary fibrosis). However, they are not currently approved or established as standard-of-care for silicosis [16][17]. High-quality human trials are still needed to determine if they are safe and effective for people with this specific disease [16][18].

Because of the lack of proven medications to reverse silicosis, the focus of your care will remain on strict exposure control, symptom management, and treating reversible complications [11].

Common questions in this guide

Can silicosis be cured or can the lung scarring be reversed?
Silicosis is permanent, and current treatments cannot remove the silica particles or reverse the lung scarring. Care focuses on stopping further exposure, easing breathing problems, treating complications, and considering lung transplantation in advanced disease.
Can silicosis continue to worsen after I stop working with silica?
Yes. Silicosis can continue to progress after exposure ends because particles already in the lungs may keep causing inflammation. Regular follow-up and lung-function monitoring remain important even after changing jobs or work environments.
What treatments can help my breathing with silicosis?
Depending on your other lung conditions and oxygen level, bronchodilator inhalers, pulmonary rehabilitation, or supplemental oxygen may help. These treatments support breathing and activity but do not reverse the scar tissue; oxygen should only be started or adjusted with medical guidance.
When is a lung transplant considered for silicosis?
Transplant evaluation may be considered for end-stage silicosis, severe progressive massive fibrosis, or rapidly worsening lung function. A transplant team weighs symptoms, breathing-test results, oxygen needs, overall health, other conditions, age, and infection status, and transplantation is major surgery rather than a guaranteed cure.
Are nintedanib or pirfenidone proven treatments for silicosis?
These antifibrotic drugs are approved for some other lung-scarring diseases but are not currently established or approved as standard treatment for silicosis. More high-quality human studies are needed, so ask a specialist about appropriate clinical trials.
Is whole-lung lavage a standard treatment for silicosis?
Whole-lung lavage may be used in the rare condition acute silicoproteinosis, but evidence does not show that it prolongs survival in typical chronic or accelerated silicosis. It is not considered a standard treatment for those forms.

Get notified when new evidence is published on Silicosis.

We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.

References

References (18)
  1. 1

    Silicosis: from pathogenesis to therapeutics.

    Yang B, Liu X, Peng C, et al.

    Frontiers in pharmacology 2025; (16()):1516200 doi:10.3389/fphar.2025.1516200.

    PMID: 39944632
  2. 2

    Silica-associated lung disease: An old-world exposure in modern industries.

    Barnes H, Goh NSL, Leong TL, Hoy R

    Respirology (Carlton, Vic.) 2019; (24(12)):1165-1175 doi:10.1111/resp.13695.

    PMID: 31517432
  3. 3

    Silicosis mortality trends and new exposures to respirable crystalline silica - United States, 2001-2010.

    Bang KM, Mazurek JM, Wood JM, et al.

    MMWR. Morbidity and mortality weekly report 2015; (64(5)):117-20.

    PMID: 25674992
  4. 4

    Severe Silicosis in Engineered Stone Fabrication Workers - California, Colorado, Texas, and Washington, 2017-2019.

    Rose C, Heinzerling A, Patel K, et al.

    MMWR. Morbidity and mortality weekly report 2019; (68(38)):813-818 doi:10.15585/mmwr.mm6838a1.

    PMID: 31557149
  5. 5

    The Burden of Silicosis in Michigan: 1988-2016.

    Reilly MJ, Timmer SJ, Rosenman KD

    Annals of the American Thoracic Society 2018; (15(12)):1404-1410 doi:10.1513/AnnalsATS.201802-117OC.

    PMID: 30188758
  6. 6

    Artificial Stone Silicosis: Rapid Progression Following Exposure Cessation.

    León-Jiménez A, Hidalgo-Molina A, Conde-Sánchez MÁ, et al.

    Chest 2020; (158(3)):1060-1068 doi:10.1016/j.chest.2020.03.026.

    PMID: 32563682
  7. 7

    RAB20 deficiency promotes the development of silicosis via NLRP3 inflammasome.

    Peng Z, Duan M, Zhao K, et al.

    Frontiers in immunology 2022; (13()):967299 doi:10.3389/fimmu.2022.967299.

    PMID: 36131930
  8. 8

    Role of metabolic reprogramming in pro-inflammatory cytokine secretion from LPS or silica-activated macrophages.

    Marrocco A, Ortiz LA

    Frontiers in immunology 2022; (13()):936167 doi:10.3389/fimmu.2022.936167.

    PMID: 36341426
  9. 9

    [Lung transplantation for phase Ⅲ silicosis: a series of 32 cases].

    Mao WJ, Chen JY, Zheng MF, et al.

    Zhonghua wai ke za zhi [Chinese journal of surgery] 2016; (54(12)):902-907 doi:10.3760/cma.j.issn.0529-5815.2016.12.006.

    PMID: 27916032
  10. 10

    What is expected in lung function after lung transplantation due to end-stage pulmonary silicosis?

    Sidney-Filho LA, Watte G, Dos Santos PAR, et al.

    Clinical transplantation 2017; (31(11)) doi:10.1111/ctr.13105.

    PMID: 28871617
  11. 11

    Lung transplantation: candidate selection and timing of transplant.

    Shah P, Neujahr DC

    Current opinion in organ transplantation 2021; (26(3)):302-308 doi:10.1097/MOT.0000000000000879.

    PMID: 33938467
  12. 12

    Single versus double lung transplantation outcomes in artificial stone silicosis: a single-centre retrospective cohort study.

    Dotan M, Rosengarten D, Azem K, et al.

    BMJ open respiratory research 2025; (12(1)) doi:10.1136/bmjresp-2024-002703.

    PMID: 41027675
  13. 13

    Single versus double lung transplantation in patients with pneumoconiosis: a retrospective cohort study.

    Chen C, Huang Y, Li Z, et al.

    Journal of occupational medicine and toxicology (London, England) 2026; (21(1)).

    PMID: 42675498
  14. 14

    Efficacy and safety of a whole lung lavage program for artificial stone silicosis.

    Barnes H, Pilcher D, Coull J, et al.

    Journal of thoracic disease 2024; (16(11)):7630-7639 doi:10.21037/jtd-24-1050.

    PMID: 39678831
  15. 15

    The Effectiveness of Whole Lung Lavage in Pneumoconiosis: A Systematic Review and Meta-Analysis.

    Zeng Y, Jiang Y, Banks DE

    Journal of occupational and environmental medicine 2022; (64(8)):e492-e499 doi:10.1097/JOM.0000000000002599.

    PMID: 35732044
  16. 16

    Toward targeted treatments for silicosis.

    Barnes H, Lam M, Tate MD, Hoy R

    Current opinion in pulmonary medicine 2024; (30(2)):185-194 doi:10.1097/MCP.0000000000001020.

    PMID: 37851380
  17. 17

    Silicosis: New Challenges from an Old Inflammatory and Fibrotic Disease.

    Handra CM, Gurzu IL, Chirila M, Ghita I

    Frontiers in bioscience (Landmark edition) 2023; (28(5)):96 doi:10.31083/j.fbl2805096.

    PMID: 37258484
  18. 18

    Pirfenidone ameliorates silica-induced lung inflammation and fibrosis in mice by inhibiting the secretion of interleukin-17A.

    Cao ZJ, Liu Y, Zhang Z, et al.

    Acta pharmacologica Sinica 2022; (43(4)):908-918 doi:10.1038/s41401-021-00706-4.

    PMID: 34316030

This page describes silicosis treatment and care options for informational purposes only and does not constitute medical advice. Your lung specialist and occupational-medicine team should tailor exposure control, oxygen, rehabilitation, and transplant decisions to your condition.